Comparison of Abeona Therapeutics Inc. (ABEO) and PTC Therapeutics Inc. (NASDAQ:PTCT)

We will be contrasting the differences between Abeona Therapeutics Inc. (NASDAQ:ABEO) and PTC Therapeutics Inc. (NASDAQ:PTCT) as far as risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Abeona Therapeutics Inc. 5.34M 59.69 45.03M -0.96 0.00
PTC Therapeutics Inc. 256.43M 6.65 78.48M -1.70 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Abeona Therapeutics Inc. and PTC Therapeutics Inc.

Profitability

Table 2 provides the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Abeona Therapeutics Inc. -843.26% -27.7% -26.4%
PTC Therapeutics Inc. -30.60% -32.7% -13.6%

Volatility & Risk

Abeona Therapeutics Inc.’s current beta is 1.85 and it happens to be 85.00% more volatile than Standard and Poor’s 500. From a competition point of view, PTC Therapeutics Inc. has a 2.26 beta which is 126.00% more volatile compared to Standard and Poor’s 500.

Liquidity

The Current Ratio of Abeona Therapeutics Inc. is 11.1 while its Quick Ratio stands at 11.1. The Current Ratio of rival PTC Therapeutics Inc. is 2.7 and its Quick Ratio is has 2.6. Abeona Therapeutics Inc. is better equipped to clear short and long-term obligations than PTC Therapeutics Inc.

Analyst Ratings

Abeona Therapeutics Inc. and PTC Therapeutics Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Abeona Therapeutics Inc. 0 0 2 3.00
PTC Therapeutics Inc. 0 1 3 2.75

$22.5 is Abeona Therapeutics Inc.’s consensus price target while its potential upside is 238.35%. Competitively PTC Therapeutics Inc. has a consensus price target of $50, with potential upside of 68.07%. The results provided earlier shows that Abeona Therapeutics Inc. appears more favorable than PTC Therapeutics Inc., based on analyst belief.

Insider and Institutional Ownership

The shares of both Abeona Therapeutics Inc. and PTC Therapeutics Inc. are owned by institutional investors at 72.9% and 94.5% respectively. Insiders owned roughly 33.5% of Abeona Therapeutics Inc.’s shares. Competitively, insiders own roughly 3.31% of PTC Therapeutics Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Abeona Therapeutics Inc. 9.88% 2.85% -33.26% -43.15% -42.97% -43.15%
PTC Therapeutics Inc. -2.82% -5.5% -26.52% -9.04% 106.09% 106.95%

For the past year Abeona Therapeutics Inc. has -43.15% weaker performance while PTC Therapeutics Inc. has 106.95% stronger performance.

Summary

On 7 of the 12 factors Abeona Therapeutics Inc. beats PTC Therapeutics Inc.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The companyÂ’s lead programs are ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV-based gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the company is developing plasma-based protein therapy pipeline, including SDF Alpha, an alpha-1 protease inhibitor for inherited COPD using its proprietary salt diafiltration ethanol-free process. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered, small molecule drugs that target post-transcriptional control processes. The companyÂ’s lead product is Translarna (ataluren), for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and which is in phase III clinical trials to treat cystic fibrosis caused by nonsense mutations. It also develops Translarna, which is in Phase II clinical trials for the treatment of mucopolysaccharidosis type I caused by nonsense mutation, nonsense mutation aniridia, and nonsense mutation Dravet syndrome/CDKL5; and RG7916 that is in Phase I clinical trials to treat spinal muscular atrophy. In addition, the companyÂ’s product candidate in cancer stem cell program include PTC596, an orally bioavailable and potent small molecule, which has completed phase I clinical trials that targets tumor stem cell populations by reducing the activity and amount of a protein called BMI1. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; and research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey.